Health Care & Life Sciences » Pharmaceuticals | Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals PLC | Income Statement

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
872
1,173
1,325
1,488
1,619
1,891
Cost of Goods Sold (COGS) incl. D&A
181
244
201
207
262
323
Gross Income
691
929
1,124
1,281
1,356
1,568
SG&A Expense
328
472
583
654
743
910
EBIT
363
457
-
627
614
658
Unusual Expense
27
261
50
36
87
44
Non Operating Income/Expense
2
9
1
3
10
7
Interest Expense
27
53
57
62
76
77
Pretax Income
308
152
436
532
441
529
Income Tax
92
94
106
135
48
80
Equity in Affiliates
-
-
-
-
1
2
Consolidated Net Income
216
57
330
397
488
447
Net Income
216
58
330
397
488
447
Net Income After Extraordinaries
216
58
330
397
488
447
Net Income Available to Common
216
58
330
397
488
447
EPS (Basic)
3.51
0.93
5.23
6.41
7.96
7.30
Basic Shares Outstanding
58
60
61
61
60
60
EPS (Diluted)
3.51
0.93
5.23
6.41
7.96
7.30
Diluted Shares Outstanding
62
63
63
62
61
61
EBITDA
445
591
650
741
779
875
Minority Interest Expense
-
1
-
-
-
-

About Jazz Pharmaceuticals

View Profile
Address
Waterloo Exchange
Dublin Dublin 4
Ireland
Employees -
Website http://www.jazzpharma.com
Updated 07/08/2019
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.